

**Table S5: Sub-group Analyses for the Association between SDMA and Outcomes in the HEMO Study**

Strata (N)	Cardiac Death		Sudden Cardiac Death		First Cardiovascular Event or Any-Cause Death		Any-Cause Death	
	HR (95% CI)	P <sup>1</sup>	HR (95% CI)	P <sup>1</sup>	HR (95% CI)	P <sup>1</sup>	HR (95% CI)	P <sup>1</sup>
Entire Sample Overall (1276)	1.40 (1.03-1.92)		1.40 (0.96-2.06)		0.98 (0.83-1.16)		1.21 (1.00-1.47)	
Age < 59 years (638)	1.33 (0.62-2.85)	0.9	1.46 (0.51-4.20)	0.9	0.89 (0.62-1.27)	0.5	1.16 (0.76-1.79)	0.8
Age ≥ 59 years (638)	1.43 (0.97-2.11)		1.38 (0.91-2.11)		1.03 (0.83-1.28)		1.23 (0.96-1.58)	
Male (552)	1.30 (0.78-2.17)	0.6	1.19 (0.59-2.41)	0.5	1.16 (0.75-1.80)	0.3	1.31 (0.97-1.77)	0.4
Female (724)	1.48 (1.13-1.94)		1.57 (1.09-2.27)		0.90 (0.76-1.07)		1.15 (0.96-1.37)	
Non-Black (474)	1.25 (0.78-2.00)	0.4	1.31 (0.68-2.51)	0.7	0.97 (0.69-1.36)	0.9	1.16 (0.85-1.59)	0.7
Black (801)	1.65 (1.13-2.42)		1.54 (1.09-2.18)		0.99 (0.76-1.31)		1.26 (0.93-1.71)	
Diabetes = No (699)	1.33 (0.68-2.59)	0.8	1.81 (0.71-4.59)	0.5	0.99 (0.75-1.32)	0.9	1.24 (0.87-1.76)	0.8
Diabetes = Yes (571)	1.47 (1.10-1.98)		1.29 (0.93-1.80)		0.99 (0.80-1.21)		1.18 (0.96-1.46)	
Cardiac Disease = No (271)	1.14 (0.42-3.12)	0.7	2.74 (0.53-14.1)	0.4	0.95 (0.56-1.62)	0.9	1.21 (0.75-1.94)	0.9
Cardiac Disease = Yes (1005)	1.41 (1.03-1.91)		1.35 (0.96-1.90)		0.98 (0.81-1.19)		1.21 (0.99-1.47)	
GI Disease = No (798)	1.71 (1.09-2.68)	0.3	1.75 (0.86-3.57)	0.4	1.10 (0.87-1.38)	0.1	1.31 (1.00-1.71)	0.3
GI Disease = Yes (478)	1.18 (0.76-1.83)		1.15 (0.65-2.04)		0.85 (0.69-1.05)		1.12 (0.88-1.41)	
BMI < 18 kg/m <sup>2</sup> (42)	2.43 (0.66-8.94)	0.4	4.66 (0.52-42.1)	0.2	2.09 (0.43-10.3)	0.3	1.50 (0.48-4.71)	0.7
BMI 18 to 25 kg/m <sup>2</sup> (621)	1.29 (0.78-2.14)		1.20 (0.54-2.62)		1.05 (0.82-1.33)		1.46 (1.06-2.00)	
BMI > 25 kg/m <sup>2</sup> (613)	1.45 (0.93-2.25)		1.45 (0.96-2.21)		0.91 (0.70-1.18)		1.03 (0.78-1.38)	
Albumin < 3.6 g/dL (566)	1.26 (0.82-1.94)	0.4	1.18 (0.71-1.95)	0.3	0.95 (0.74-1.22)	0.7	1.21 (0.94-1.56)	0.9
Albumin ≥ 3.6 g/dL (704)	1.72 (1.00-2.97)		2.01 (0.97-4.14)		1.03 (0.77-1.39)		1.21 (0.82-1.79)	
Standard Dose (641)	1.28 (0.76-2.15)	0.6	1.32 (0.79-2.20)	0.7	0.95 (0.73-1.24)	0.7	1.07 (0.75-1.53)	0.3
High Dose (635)	1.53 (1.12-2.08)		1.48 (0.93-2.36)		1.01 (0.84-1.22)		1.36 (1.04-1.79)	
Low-Flux (640)	1.09 (0.71-1.67)	0.1	1.15 (0.75-1.77)	0.2	0.91 (0.76-1.09)	0.3	1.14 (0.87-1.49)	0.6
High-Flux (636)	1.94 (1.17-3.21)		1.77 (0.95-3.28)		1.02 (0.82-1.28)		1.29 (0.95-1.74)	
RKF = No (842)	1.38 (0.96-1.99)	0.8	1.28 (0.81-2.02)	0.6	1.09 (0.87-1.36)	0.2	1.13 (0.86-1.48)	0.3
RKF = Yes (433)	1.48 (0.89-2.47)		1.78 (0.68-4.65)		0.80 (0.55-1.16)		1.41 (1.07-1.86)	

*Abbreviation:* HR, Hazard Ratio; CI, Confidence Interval; SDMA, Symmetric Dimethylarginine; GI, Gastrointestinal; BMI, Body Mass Index; RKF, Residual Kidney Function

HR represents increase in risk per 2-fold increase in ADMA or SDMA concentrations. Modeled as natural log transformed variable/natural log of 2. Model 4 adjusted for age, sex, race, Index of Coexisting Disease (ICED) severity score, cause of end-stage renal disease, body mass index (categorized as <18, 18 to 25 and >25 kg/m<sup>2</sup>), systolic blood pressure (categorized as <130, 130-160 and >160 mm Hg), albumin, relative volume removed on dialysis and residual kidney function (urinary stdKt/V<sub>UREA</sub> calculated from urinary urea clearance).

<sup>1</sup> P-interactions between groups for the subgroup analyses.